$INO Funny, people say peer article not going to make a difference in the stock price. That’s BS. That’s the exact reason why it went down after interim Phase 1 results came out is because the analysts stated there wasn’t enough data. I guarantee if the peer review proves robust stellar results that many other vaccines have little to no data that INOVIO stock will go up. Especially with funding. Look what happened when the DOD wrote a $71M contract just for the proprietary CELLECTRA dosing device. They believe in their technology and also stated they leaving it open to use INO-4800 in a Phase 2 context for the DOD, healthcare workers and people with health issues.
  • 18
18 Likes